IDH1 and central nervous system cancer: IDH-mut glioma had better OS (p < 0.001) and PFS (p < 0.001) compared with patients without IDH1 mutation (Supplementary Figures 3C, D), which was in agreement with studies reported elsewhere (26, 27).